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In the majority of patients with colorectal carcinoma the tumour
will be resectable, and thus potentially curable, at the time of
presentation. However, despite the high resectability rate and
improving surgical therapy, nearly half of the patients will ulti-
mately die from recurrent disease. Safe and effective adjuvant
therapy is desperately needed, particularly for patients with
Dukes￿ stage B2—3 and C carcinoma, which constitute 60—70% of
the population presenting with colorectal cancer.
Since its introduction over 35 years ago, 5-fluorouracil (5-FU)
has remained the cornerstone of adjuvant treatment of colorectal
carcinoma. However, none of the regimens currently available is
a satisfactory answer to the problem of recurrent disease. Efforts
to devise more effective adjuvant treatments include various
approaches. In addition to attempts to modulate biochemically the
cytotoxic activity of 5-FU, these include the development of new
agents and of immunotherapy (Fuchs and Mayer, 1995; Sinicrope
and Sugarman, 1995; Rustum et al, 1997). Another approach
comprises the investigation of local—regional treatment strategies,
in particular administration of drugs into the portal vein or
intraperitoneally (Saltz and Kelsen, 1997). It has been suggested
that the beneficial effects of portal vein infusion are attributable to
the effects of immediate, perioperative systemic treatment rather
than to its hepatic-directed nature (Vaughn and Haller, 1997).
Also, early use of intraperitoneal treatment may be needed for best
results (Cunliffe and Sugarbaker, 1989; Saltz and Kelsen, 1997).
The apparent interest in immediate post-operative local and/or
systemic adjuvant 5-FU therapy necessitates the delineation of its
hazards for anastomotic repair in the intestine. The early phase of
anastomotic healing is characterized by a transient loss of strength
in the anastomosed segment (Hendriks and Mastboom, 1990).
Further reduction in wound strength in this period may compro-
mise anastomotic integrity and increase the risk of anastomotic
dehiscence, which is a potentially devastating surgical complica-
tion. Previous studies in our laboratory have shown that adminis-
tration of 5-FU on the day of surgery and on the next 2 days does
not significantly reduce strength in experimental intestinal anasto-
moses (de Waard et al, 1993, 1995a). However, a 7-day course of
intraperitoneal 5-FU, starting on the day of surgery, severely
reduces anastomotic strength as measured 7 days after operation
(Graf et al, 1992; de Waard et al, 1995b). The present study
addresses the question of whether postponement of the start of 5-
FU administration until the first, second or third day after opera-
tion can prevent these negative effects on the development of
anastomotic strength during the first post-operative week.
MATERIALS AND METHODS
Animals
Altogether, 120 male outbred Wistar/Cpb:WU rats, weighing
between 250 and 320 g, were used. They were housed two animals
per cage and had free access to water and standard laboratory
chow (diet AM II, Hope Farms, Woerden, The Netherlands). The
animals were divided into two equal groups, one for the experi-
ment with intravenous 5-FU, the other for the experiment with
intraperitoneal 5-FU. Within each group, five subgroups of 12 rats
each were formed: a control group (C) and four experimental
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Summary Early post-operative local or systemic administration of 5-fluorouracil (5-FU) is under investigation as a means to improve
outcome after resection of intestinal malignancies. It is therefore quite important to delineate accurately its potentially negative effects on
anastomotic repair. Five groups (n = 24) of rats underwent resection and anastomosis of both ileum and colon: a control group and four
experimental groups receiving daily 5-FU, starting immediately after operation or after 1, 2 or 3 days. Within each group, the drug (or saline)
was delivered either intraperitoneally (n = 12) or intravenously (n = 12). Animals were killed 7 days after operation and healing was assessed
by measurement of anastomotic bursting pressure, breaking strength and hydroxyproline content. In all cases, 5-FU treatment from the day
of operation or from day 1 significantly (P < 0.025) and severely suppressed wound strength; concomitantly, the anastomotic hydroxyproline
content was reduced. Depending on the location of the anastomosis and the route of 5-FU administration, even a period of 3 days between
operation and first dosage seemed insufficient to prevent weakening of the anastomosis. The effects of intravenous administration, though
qualitatively similar, were quantitatively less dramatic than those observed after intraperitoneal delivery. Post-operative treatment with 5-FU,
if started within the first 3 days after operation, is detrimental to anastomotic strength and may compromise anastomotic integrity.
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FU0) or on the first (5-FU1), second (5-FU2) or third (5-FU3)
post-operative day. All animals were killed 7 days after operation.
The study was approved by the Animal Ethics Review
Committee of the Faculty of Medicine, University of Nijmegen.
Drug administration
5-FU (Abic, Netanya, Israel) was given in a dose of 20 mg kg—1 body
weight once a day. This is the same dose that we used previously (de
Waard et al, 1993, 1995a,b) and represents the highest dose which,
in combination with surgery, did not result in a significant mortality.
5-FU was injected as a bolus in a concentration of 1 mg ml—1 saline
intraperitoneally and in a concentration of 2 mg ml—1 saline intra-
venously (through the vein of the tail). In those experimental groups
in which 5-FU was not started immediately after operation, animals
received daily saline instead. The animals in the two control groups
received saline daily throughout the experiment.
Operative procedure
During halothane anaesthesia, a midline incision was made and
1 cm of both small and large bowel were resected, at 15 cm proximal
to the ileocaecal junction, and 3 cm proximal to the rectal peritoneal
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Figure 1 Bursting pressure in anastomotic segments. Circles represent individual animals and horizontal bars the median values; open circles, rupture outside
anastomosis; closed circles, rupture within suture line. (A) Ileum, intraperitoneal 5-FU. (B) Ileum, intravenous 5-FU. (C) Colon, intraperitoneal 5-FU. (D) Colon,
intravenous 5-FU. #Significant (P < 0.025, see Materials and methods) difference between experimental groups and the control groupreflection respectively. Continuity was restored microsurgically by
the construction of an inverted one-layer seromuscular end-to-end
anastomosis with eight interrupted sutures of 8 ´ 0 monofilament
material (Ethicon, Sommerville, NJ, USA). The abdomen was closed
in two layers with a continuous 3 ´ 0 silk suture for the fascia and
staples for the skin.
Analytical procedures
The rats were killed by an intraperitoneal overdose of sodium
pentobarbital. After opening the abdominal wound and identifying
the anastomoses, the adhesions were cut as far as possible without
injuring the intestine. An intestinal segment with the anastomosis
in the middle was removed, with the sutures left in place. This
segment was attached to an infusion pump filled with methylene
blue-stained saline. The pressure was raised with an infusion rate
of 4 ml min—1 and recorded graphically. Both the bursting pressure,
that is the maximum pressure recorded immediately before sudden
loss of pressure, and the site of rupture were noted. Thereafter, the
segment was placed in a tensiometer and the breaking strength was
recorded. Thus, both the bursting pressure and breaking strength
were measured in the same anastomotic segment. The validity of
this procedure had been confirmed in a pilot experiment.
Anastomotic breaking strength was compared in two groups of
rats, either measured directly or after the procedure used for
measuring the bursting pressure, and found to be similar in both
groups (de Waard et al, 1995a). The anastomotic segment was then
cleaned from the surrounding tissue and a 5-mm segment with the
suture line in the middle was collected. The samples were frozen
immediately and stored in liquid nitrogen until processing. After
weighing, the samples were pulverized and lyophilized and the
hydroxyproline content was measured by high-performance liquid
chromatography (HPLC) after hydrolysis with 6 N hydrochloric
acid and derivatization with dabsyl chloride.
Statistical analysis
To correct for the fact that multiple comparisons were made, pair-
wise comparisons of groups were performed (with a two-tailed
Mann—Whitney test) using a level of significance of a¢ = 2 a/k,
where  k is the number of pairwise comparisons. For instance,
differences between the four experimental groups and the control
group were considered significant (a = 0.05) at P < a¢, where a¢ =
2 ´ 0.05/4 = 0.025.
RESULTS
During the experiment two animals died prematurely, both from
groups receiving intraperitoneal 5-FU. In the 5-FU0 group, one rat
died from anastomotic leakage 4 days after operation; in the 5-FU1
group, one rat died from unknown causes 7 days after operation.
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Figure 2 Anastomotic breaking strength. Data represent median values (l) and range (vertical lines); boxes delineate the 95% confidence interval. (A) Ileum,
intraperitoneal 5-FU. (B) Ileum, intravenous 5-FU. (C) Colon, intraperitoneal 5-FU. (D) Colon, intravenous 5-FU. #Significant (P < 0.025, see Materials and
methods) difference between experimental groups and the control group
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300At the end of the experiment, the average body weight in the
control groups was equal to that immediately before operation. In
all experimental groups, body weight was reduced. Average weight
loss at day 7, calculated with respect to the weight before operation,
was 28% in the 5-FU0 group, 24% in the 5-FU1 group, 17% in the
5-FU2 group and 13% in the 5-FU3 group after intraperitoneal drug
administration. Corresponding values after intravenous 5-FU were
20, 19, 13 and 9% respectively. Statistical comparison (Mann—
Whitney) between each experimental group and the control group
yielded significance (P < 0.0001) in all cases.
Anastomotic strength was assessed in two ways: by the bursting
pressure and, subsequently, by the breaking strength. Figure 1
depicts the bursting pressures measured in the individual anasto-
motic segments. Within the intraperitoneal group, the bursting
pressure was strongly and significantly reduced in the 5-FU0, 5-
FU1 and 5-FU2 groups, both in ileum (Figure 1A) and in colon
(Figure 1C). Also, the bursting site, which was almost invariably
outside the wound area in the control groups, had shifted signifi-
cantly (Fisher￿s exact test) to the actual suture line. If 5-FU was
started on the third day after operation (5-FU3), the bursting pres-
sure in the anastomotic segment was equal to that of controls and
significantly (P < 0.0001) higher than in each of the other 5-FU
groups. However, in the ileum, wound strength was still reduced
as indicated by the significant (P = 0.0046) shift in bursting site if
compared with the controls. The loss of bursting pressure in the 5-
FU groups seemed less severe if the drug was given intravenously.
In the ileum (Figure 1B) the median values of both 5-FU2 and 5-
FU3 groups were similar to that in the control group. However,
loss of strength in the 5-FU2 group was still apparent from the
significant (P < 0.0001, Fisher￿s exact test) shift of bursting site to
the wound area. In the colon (Figure 1D), significant differences
between the control and 5-FU groups were only apparent in the
bursting site, which had shifted to the suture line in the 5-FU0
(P < 0.0001) and 5-FU1 (P = 0.0006) groups.
During the measurement of the breaking strength, tearing of the
tissue always occurred within the suture line. The results are
depicted in Figure 2. Intraperitoneal administration of 5-FU led to
significant loss of ileal breaking strength (Figure 2A) in all exper-
imental groups. Nevertheless, the reduction of strength was
greatest (60%) in the 5-FU0 group and significantly (P < 0.0001)
less so in the 5-FU2 and 5-FU3 groups. In the colon (Figure 2C)
only the 5-FU0 group displayed loss of strength. If 5-FU was
given intravenously, ileal anastomoses were significantly weak-
ened in all experimental groups (Figure 2B) and colonic anasto-
moses only in the 5-FU0 and 5-FU1 groups.
The hydroxyproline content in the 5-mm tissue, which
contained the actual anastomosis, was assayed as a measure for
the presence of collagen. Figure 3 shows that intraperitoneal
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Figure 3 Anastomotic hydroxyproline content. Data represent median values (l) and range (vertical lines); boxes delineate the 95% confidence interval.
(A) Ileum, intraperitoneal 5-FU. (B) Ileum, intravenous 5-FU. (C) Colon, intraperitoneal 5-FU. (D) Colon, intravenous 5-FU. #Significant (P < 0.025, see Materials
and methods) difference between experimental groups and the control groupadministration of 5-FU led to a reduced anastomotic hydroxypro-
line content. In the colon (Figure 3C) there was a significant
decrease, with respect to the controls, in all experimental groups.
In the ileum, this was the case for the 5-FU0 and 5-FU1 groups.
Median values in the 5-FU2 and 5-FU3 groups were also lower
than that in the control group, although these differences just failed
to reach statistical significance (P = 0.0317 and P = 0.0336 respec-
tively; cf. Materials and methods section). The effect of intra-
venous 5-FU was far less pronounced. Here, the only significant
difference was observed in the ileum between the control and
5-FU0 group (Figure 3B).
DISCUSSION
Adjuvant therapy in colorectal cancer is routinely withheld until
weeks after operation. However, there exists an excellent rationale
to start therapy in the immediate post-operative period (Fisher et al,
1983; Goldie and Coldman, 1985; Harris and Mastrangelo, 1991).
Although, so far, limited information exists to support timing deci-
sions in human neoplasms, there exists a growing perception that
treatment with anti-cancer agents should begin at the day of surgery
or as soon as possible thereafter (Cunliffe and Sugarbaker, 1989;
Harris and Mastrangelo, 1991; Fielding et al, 1992).
Accepting the hypothesis that perioperative administration of 5-
FU could benefit (certain classes of) patients after resection of
intestinal malignancies, it becomes imperative to delineate accu-
rately its potential detrimental effects on the healing anastomosis.
As the early phase of the repair sequence depends heavily on
cellular proliferation, adverse effects may be expected as a result of
administration of non-specific anti-neoplastic agents during this
period. Therefore, we analysed anastomotic strength 1 week after
operation in terms of both bursting pressure and breaking strength.
The former parameter is probably more sensitive in detecting local-
ized loss of strength; a very small hole in the intestinal wall will
result in loss of bursting pressure but not necessarily in a reduction
in breaking strength. Within the present experiment, the outcome of
both measurements is quite similar. The exception, a significant
reduction in colonic bursting pressure without a concomitant reduc-
tion in breaking strength in the 5-FU1 and 5-FU2 groups after
intraperitoneal administration of 5-FU, emphasizes the necessity of
evaluating both parameters in order to draw the correct conclusion
regarding the safety of any treatment schedule.
In a recent study, Weiber et al (1994) compared colonic healing
during intraperitoneal 5-FU treatment, starting either at the day of
operation or on the third post-operative day. Their findings indi-
cate that the colonic breaking strength is not impaired when
intraperitoneal 5-FU treatment is started at the later time point. We
find this also to be true if, in addition, the bursting pressure is
taken as the parameter for strength and if 5-FU is given intra-
venously. However, it is not valid for the intestine as a whole,
because the breaking strength of ileal anastomoses remains signif-
icantly reduced in the 5-FU3 groups (Figure 2A and B).
Furthermore, our data clearly demonstrate that anti-neoplastic
therapy with 5-FU, if started on the first or second day after opera-
tion, may compromise the development of strength in intestinal
anastomoses.
Wound strength is mainly dependent on the presence of collagen
— alterations in both existing collagen, which is needed to anchor
the sutures into the submucosa, and newly synthesized collagen,
which is necessary to restore structural integrity to the bowel wall,
can affect anastomotic strength. In most of our experimental
groups, loss of strength is indeed accompanied by a significantly
reduced hydroxyproline level in the anastomotic segment. Previous
results, both in our animal model (de Waard et al, 1995b) and in
human subcutaneous grafts (Graf et al, 1994b), have demonstrated
that early post-operative intraperitoneal 5-FU treatment may
strongly inhibit collagen synthetic capacity, possibly by a direct
effect on fibroblast proliferation and collagen synthesis (de Waard
et al, 1998). As no direct effects of 5-FU on collagen degradation
are known, we suggest that reduced synthesis is primarily respon-
sible for the observed loss of anastomotic strength. Although all
experimental groups lose significantly more weight than the control
groups, it seems unlikely that the (metabolic) effects of weight loss
cause the reduction in wound strength, because nutritional deple-
tion alone leading to weight loss of a similar magnitude does not
lower anastomotic strength (Graf et al, 1994a).
The effects of intraperitoneal and intravenous 5-FU on anasto-
motic strength and hydroxyproline content appear qualitatively
similar. However, local administration of the drug seems on the
whole to result in a quantitatively more explicit response. For
instance, after intraperitoneal administration the median bursting
pressure in ileal anastomoses is reduced by 79% in the 5-FU0
group and by 55% in the 5-FU2 group; if delivered intravenously,
the median reduction in these groups is 14% and 10% respectively.
This agrees well with earlier data, which show that intraperitoneal
administration of anti-neoplastic agents leads to a greater reduc-
tion of anastomotic collagen synthetic capacity than does intra-
venous delivery (Martens et al, 1992).
In conclusion, it can be stated that, within this animal model,
post-operative systemic or intraperitoneal treatment with 5-FU,
started before the third day after surgery, leads to loss of anasto-
motic strength. It remains to be seen what this means for clinical
practice. As yet, few data are available, although trials to assess the
efficacy of immediate post-operative systemic and regional
chemotherapy are under way (P￿hlman, 1995; Vaughn and Haller,
1997). It is quite possible that, for the individual patient, a period
of suboptimal wound strength does not necessarily lead to anasto-
motic complications, as long as the strength reaches a certain
minimal — so far undefined — value that ensures anastomotic
integrity. However, clinicians should be well aware of the potential
effects of early anti-neoplastic therapy, the more so if patients are
treated presenting with conditions that may constitute additional
threats to wound integrity. These may include, for example,
malnutrition, bowel obstruction, peritonitis, (poorly controlled)
diabetes, advanced age and, possibly, others (Golub et al, 1997;
Thornton and Barbul, 1997). In these cases, the burden of two or
more negative factors could be such that the risk for anastomotic
leakage becomes unacceptable and postponement of adjuvant
therapy is indicated.
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